Division of Rheumatology, Department of Medicine.
University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA.
Curr Opin Rheumatol. 2022 Jul 1;34(4):235-244. doi: 10.1097/BOR.0000000000000877. Epub 2022 Jun 9.
Raynaud's phenomenon (RP) is a common vasospastic condition that results in digital hypoperfusion in response to cold and/or emotional stress and is associated with significant pain and disability. The aim of our review is to provide a practical approach for clinicians to inform assessment and management of patients with RP.
Autoantibodies and nailfold capillaroscopy are key investigations to stratify the risk of progression to systemic sclerosis (SSc) in patients RP, which was recently confirmed in the multicenter, very early diagnosis of systemic sclerosis (VEDOSS) project. Research has explored the complex lived-patient experience of RP including digital vasculopathy in SSc and has highlighted the need for outcome measure development to facilitate research in the field. Pharmacological treatment strategies vary significantly internationally and there is continued interest in developing surgical approaches.
We provide a practical and up-to-date approach to inform the assessment and management of patients with RP including guidance on drug initiation and escalation. Calcium channel blockers are first-line treatment and can be initiated by primary care physicians. We also highlight second-line drug therapies used for refractory RP and the potential role for surgical intervention.
雷诺现象(RP)是一种常见的血管痉挛性疾病,表现为在寒冷和/或情绪应激下手指血流量减少,并伴有明显的疼痛和功能障碍。我们撰写本文的目的是为临床医生提供一种实用的方法,以评估和管理 RP 患者。
自身抗体和甲襞毛细血管镜检查是对 RP 患者发生系统性硬化症(SSc)风险进行分层的关键检查,这一结果最近在多中心、早期系统性硬化症诊断(VEDOSS)项目中得到了证实。研究还探索了 RP 患者的复杂生活体验,包括 SSc 中的手指血管病变,并强调需要开发结局测量指标以促进该领域的研究。RP 的药物治疗策略在国际上差异很大,人们一直有兴趣开发手术方法。
我们提供了一种实用且最新的方法来评估和管理 RP 患者,包括药物起始和升级的指导。钙通道阻滞剂是一线治疗药物,可由初级保健医生开具。我们还强调了难治性 RP 的二线药物治疗方法,以及手术干预的潜在作用。